Alex Zhavoronkov — SPARQNOW

At-a-Glance

Founder and CEO of Insilico Medicine, a global clinical-stage generative AI drug discovery company.
Founded Insilico Medicine in 2014 and co-chairs the non-profit Aging Research and Drug Discovery (ARDD) conference.
Led Insilico's development of the first fully generative AI drug to reach human clinical trials, specifically Phase II trials.
Author of books including "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy."
Serves as director of the Biogerontology Research Foundation.
Holds a PhD in Physics and Mathematics from Moscow State University and a Master's in Biotechnology from Johns Hopkins University.

Biography

Alex Zhavoronkov is a Latvian-born scientist and author, best known as the founder and CEO of Insilico Medicine, a global clinical-stage generative AI drug discovery company. Founded in 2014, Insilico Medicine focuses on developing and applying deep learning methods to drug discovery, with therapeutic programs in immunology, oncology, fibrosis, and CNS.